One more gig: Steven Paul decides to extend a 35-year track record with one last shot at a big development program
Steven Paul was ready to hang up the lab coat when he stepped down near the beginning of the year as CEO of the gene therapy startup Voyager. After 35 years spent doing stints as a prominent top investigator at the National Institute of Mental Health, leading the early-stage neurosciences group at Eli Lilly and as a co-founder at Sage and Voyager, seeing out his career on some high-profile biotech boards like Alnylam seemed just right.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
